1-7 of 7
Ling Fu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract POSTER-THER-1441: Biomarker evaluation of phase 1 clinical trials of antibody-drug conjugates (ADCs) in platinum resistant ovarian cancer

Yulei Wang, Ron Firestein, Lisa Ryner, Walter Darbonne, Yinghui Guan, Shan Lu, YJ Choi, Yuanyuan Xiao, Paul Polakis, Becky Suttmann, Rupal Desai, Ling Fu, Ola Saad, Kirsten Achilles Poon, Mitch Denker, Vincent Leveque, Teiko Sumiyoshi, Mark Lackner, David Shames, Eric Humke, Daniel Mayslar
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16_Supplement): POSTER-THER-1441.
https://doi.org/10.1158/1557-3265.OVCASYMP14-POSTER-THER-1441
Published: 15 August 2015
View articletitled, Abstract POSTER-THER-1441: Biomarker evaluation of phase 1 clinical trials of antibody-drug conjugates (ADCs) in platinum resistant ovarian cancer
Journal Articles

Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer

Lisa Ryner, Yinghui Guan, Ron Firestein, Yuanyuan Xiao, Younjeong Choi, Christina Rabe, Shan Lu, Eloisa Fuentes, Ling-Yuh Huw, Mark R. Lackner, Ling Fu, Lukas C. Amler, Carlos Bais, Yulei Wang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (13): 2941–2951.
https://doi.org/10.1158/1078-0432.CCR-14-3111
Published: 30 June 2015
View articletitled, Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer
Open the PDF for Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Hartmut Koeppen, Wei Yu, Jiping Zha, Ajay Pandita, Elicia Penuel, Linda Rangell, Rajiv Raja, Sankar Mohan, Rajesh Patel, Rupal Desai, Ling Fu, An Do, Vaishali Parab, Xiaoling Xia, Tom Januario, Sharianne G. Louie, Ellen Filvaroff, David S. Shames, Ignacio Wistuba, Marina Lipkind, Jenny Huang, Mirella Lazarov, Vanitha Ramakrishnan, Lukas Amler, See-Chun Phan, Premal Patel, Amy Peterson, Robert L. Yauch
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4488–4498.
https://doi.org/10.1158/1078-0432.CCR-13-1836
Published: 01 September 2014
View articletitled, Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
Open the PDF for Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit in another window
Includes: Supplementary data
Journal Articles

Optimization of a method for preserving nucleic acids in tissue lysates from archival formalin-fixed tissue samples

Ling Fu, Rupal Desai, Thomas Holcomb, Rajiv Raja
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): B35.
https://doi.org/10.1158/DIAG-10-B35
Published: 15 August 2014
View articletitled, Optimization of a method for preserving nucleic acids in tissue lysates from archival formalin-fixed tissue samples
Journal Articles

A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission

Stanley B. Kaye, Louis Fehrenbacher, Robert Holloway, Amnon Amit, Beth Karlan, Brian Slomovitz, Paul Sabbatini, Ling Fu, Robert L. Yauch, Ilsung Chang, Josina C. Reddy
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (23): 6509–6518.
https://doi.org/10.1158/1078-0432.CCR-12-1796
Published: 29 November 2012
View articletitled, A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
Open the PDF for A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission in another window
Includes: Supplementary data
Journal Articles

Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened

Tracy Tang, Jean Y. Tang, Dongwei Li, Mike Reich, Christopher A. Callahan, Ling Fu, Robert L. Yauch, Frank Wang, Karen Kotkow, Kris S. Chang, Elana Shpall, Angela Wu, Lee L. Rubin, James C. Marsters, Jr., Ervin H. Epstein, Jr., Ivor Caro, Frederic J. de Sauvage
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3378–3387.
https://doi.org/10.1158/1078-0432.CCR-10-3370
Published: 15 May 2011
View articletitled, Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
Open the PDF for Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened in another window
Includes: Supplementary data
Journal Articles

Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Robert L. Yauch, Thomas Januario, David A. Eberhard, Guy Cavet, Wenjing Zhu, Ling Fu, Thinh Q. Pham, Robert Soriano, Jeremy Stinson, Somasekar Seshagiri, Zora Modrusan, Chin-Yu Lin, Vincent O'Neill, Lukas C. Amler
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (24): 8686–8698.
https://doi.org/10.1158/1078-0432.CCR-05-1492
Published: 16 December 2005
View articletitled, Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
Open the PDF for Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients in another window